Advertisement

Jehovah’s Witnesses

  • Ronald HuangEmail author
Chapter

Abstract

Patients may decline blood product transfusions for many reasons. The most common reason for declining transfusion is a religious objection among Jehovah’s Witnesses. Caring for Jehovah’s Witnesses may present a unique challenge to providers around the time of surgery when blood loss can be expected. However, with proper planning and management, most surgeries can be performed safely with outcomes comparable to patients who accept transfusions.

Keywords

Preoperative Perioperative Jehovah’s Witnesses Patients who decline transfusion 

References

  1. 1.
    Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Intern Med. 2012;172(15):1154–60.CrossRefGoogle Scholar
  2. 2.
    Jassar AS, Ford PA, Haber HL, et al. Cardiac surgery in Jehovah’s Witness patients: ten-year experience. Ann Thorac Surg. 2012;93(1):19–25.CrossRefGoogle Scholar
  3. 3.
    Frank SM, Wick EC, Dezern AE, et al. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. Transfusion. 2014;54(10 Pt 2):2668–77. Open image in new windowGoogle Scholar
  4. 4.
    Scharman CD, Burger D, Shatzel JJ, Kim E, DeLoughery TG. Treatment of individuals who cannot receive blood products for religious or other reasons. Am J Hematol. 2017;92(12):1370–1381. Open image in new windowGoogle Scholar
  5. 5.
    Resar LM, Wick EC, Almasri TN, et al. Bloodless medicine: current strategies and emerging treatment paradigms. Transfusion. 2016;56(10):2637–47.CrossRefGoogle Scholar
  6. 6.
    Lawson T, Ralph C. Perioperative Jehovah’s Witnesses: a review. Br J Anaesth. 2015;115(5):676–87.CrossRefGoogle Scholar
  7. 7.
  8. 8.
    Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.CrossRefGoogle Scholar
  9. 9.
    Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012;14(3):CD005011.Google Scholar
  10. 10.
    Ranucci M, Isgrò G, Soro G, Conti D, De Toffol B. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg. 2008;143(3):296–304; discussion 304.CrossRefGoogle Scholar
  11. 11.
    Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299(19):2304–12.CrossRefGoogle Scholar
  12. 12.
    Mer M, Hodgson E, Wallis L, et al. Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients. Transfusion. 2016;56(10):2631–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine, Division of General Internal MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations